Elderly Head and Neck Cancer (ELAN) study: Personalized treatment according to geriatric assessment in patients age 70 or older: First prospective trials in patients with squamous cell cancer of the head and neck (SCCHN) unsuitable for surgery.
Joel Guigay
Honoraria - Merck Serono
Research Funding - GlaxoSmithKline; Merck Serono; Novartis; Sanofi
Herve Le Caer
Research Funding - Sandoz
Cecile Mertens
No relevant relationships to disclose
Cecile Ortholan
No relevant relationships to disclose
Emmanuel Blot
No relevant relationships to disclose
Yungan Tao
No relevant relationships to disclose
Frederic Peyrade
Honoraria - Merck Serono
Yoann Pointreau
No relevant relationships to disclose
Pierre Guillet
No relevant relationships to disclose
Cedrik Lafond
No relevant relationships to disclose
Karen Benezery
No relevant relationships to disclose
Sophie Renard-Oldrini
No relevant relationships to disclose
Julia Villa
No relevant relationships to disclose
Georges Garnier
No relevant relationships to disclose
Marc Alfonsi
Honoraria - Merck Serono
Naima Lezghed
No relevant relationships to disclose
Nadejda Vintonenko
No relevant relationships to disclose
Dominique Schwob
No relevant relationships to disclose
Perrine Capolino
No relevant relationships to disclose
Anne Auperin
No relevant relationships to disclose